Medexus Pharmaceuticals Statistics
Total Valuation
Medexus Pharmaceuticals has a market cap or net worth of 44.76 million. The enterprise value is 84.22 million.
| Market Cap | 44.76M |
| Enterprise Value | 84.22M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medexus Pharmaceuticals has 24.46 million shares outstanding. The number of shares has increased by 21.29% in one year.
| Shares Outstanding | 24.46M |
| Shares Change (YoY) | +21.29% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | 8.94% |
| Owned by Institutions (%) | 8.39% |
| Float | 22.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 14.35 |
| PS Ratio | 0.35 |
| PB Ratio | 1.31 |
| P/FCF Ratio | 2.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.53, with an EV/FCF ratio of 4.91.
| EV / Earnings | n/a |
| EV / Sales | 0.75 |
| EV / EBITDA | 4.53 |
| EV / EBIT | 6.59 |
| EV / FCF | 4.91 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 1.65.
| Current Ratio | 1.09 |
| Quick Ratio | 0.44 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | 2.68 |
| Debt / FCF | 2.90 |
| Interest Coverage | 1.01 |
Financial Efficiency
Return on equity (ROE) is -0.72% and return on invested capital (ROIC) is -34.12%.
| Return on Equity (ROE) | -0.72% |
| Return on Assets (ROA) | -0.14% |
| Return on Capital (ROIC) | -34.12% |
| Revenue Per Employee | 1.38M |
| Profits Per Employee | -2,651 |
| Employee Count | 82 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.79 |
Taxes
In the past 12 months, Medexus Pharmaceuticals has paid 318,981 in taxes.
| Income Tax | 318,981 |
| Effective Tax Rate | 314.03% |
Stock Price Statistics
The stock price has increased by +32.04% in the last 52 weeks. The beta is 1.87, so Medexus Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.87 |
| 52-Week Price Change | +32.04% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.48 |
| Relative Strength Index (RSI) | 85.29 |
| Average Volume (20 Days) | 18,105 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medexus Pharmaceuticals had revenue of 112.94 million and -217,404 in losses. Loss per share was -0.01.
| Revenue | 112.94M |
| Gross Profit | 59.39M |
| Operating Income | 12.77M |
| Pretax Income | 101,577 |
| Net Income | -217,404 |
| EBITDA | 18.57M |
| EBIT | 12.77M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 5.25 million in cash and 49.84 million in debt, giving a net cash position of -44.59 million or -1.82 per share.
| Cash & Cash Equivalents | 5.25M |
| Total Debt | 49.84M |
| Net Cash | -44.59M |
| Net Cash Per Share | -1.82 |
| Equity (Book Value) | 30.29M |
| Book Value Per Share | 1.24 |
| Working Capital | 6.26M |
Cash Flow
In the last 12 months, operating cash flow was 17.43 million and capital expenditures -264,968, giving a free cash flow of 17.16 million.
| Operating Cash Flow | 17.43M |
| Capital Expenditures | -264,968 |
| Free Cash Flow | 17.16M |
| FCF Per Share | 0.70 |
Margins
Gross margin is 52.59%, with operating and profit margins of 11.31% and -0.19%.
| Gross Margin | 52.59% |
| Operating Margin | 11.31% |
| Pretax Margin | 0.09% |
| Profit Margin | -0.19% |
| EBITDA Margin | 16.45% |
| EBIT Margin | 11.31% |
| FCF Margin | 15.19% |
Dividends & Yields
Medexus Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.29% |
| Shareholder Yield | -21.29% |
| Earnings Yield | -0.55% |
| FCF Yield | 43.31% |
Analyst Forecast
| Price Target | 3.00 |
| Price Target Difference | 63.93% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 19, 2018. It was a reverse split with a ratio of 1:15.
| Last Split Date | Dec 19, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:15 |